Regulatory milestones

Forest Laboratories Inc. (NYSE:FRX) was up $0.42 to $44.41 on Friday after FDA approved Fetzima levomilnacipran to treat major depressive disorder (MDD) in adults. The company said the product will be available in the U.S. next quarter. Forest has exclusive rights to develop and commercialize Fetzima in the U.S. and Canada from Laboratoires Pierre Fabre S.A.